A rapid and non-pathogenic assay for association of Mycobacterium tuberculosis gyrBA mutations and fluoroquinolone resistance using recombinant Mycobacterium smegmatis. Issue 23 (10th November 2018)

• Record Type: Journal Article
• Authors: Yoshida, Mitsunori; Nakata, Noboru; Miyamoto, Yuji; Fukano, Hanako; Ato, Manabu; Hoshino, Yoshihiko
• Is Part Of: FEMS microbiology letters. Volume 365:Issue 23(2018:Dec.)
• Publication Date: 2018-11-10
• Subjects: surrogate system for drug susceptibility -- recombinant mycobacteria -- fitness cost -- sitafloxacin; Microbiology -- Periodicals; 579
• DOI: 10.1093/femsle/fny266
• Languages: English
• ISSNs: 0378-1097

Abstract

Abstract: We developed a method involving recombinant Mycobacterium bovis bacillus Calmette–Guérin (BCG) and recombinant Mycobacterium smegmatis to determine which mutations in Mycobacterium tuberculosis ( Mtb ) gyrBA are associated with fluoroquinolone (FQ) resistance. The minimal inhibitory concentration (MIC) for FQ for recombinant strains with wild-type Mtb gyrBA was equivalent to that for strains with intrinsic gyrBA . Among 27 gyrBA mutations, the fold-changes in FQ MIC for M. smegmatis and M. bovis BCG backgrounds were comparable and were in part equivalent to those previously reported for recombinant Mtb strains. Mutations at position 90 or 94 of gyrA conferred strong and synergistic FQ resistance, which may be associated with the clinical observation that isolates carrying these mutations are the most or second most frequent. Sitafloxacin hydrate had the lowest MIC among the FQs tested in this study, which is similar to findings from a previous in vivo animal study. Most gyrBA mutations detected in clinical Mtb isolates could confer FQ resistance, but several mutations reduced bacterial growth rates. Overall, recombinant M. smegmatis appears to be a beneficial surrogate system to evaluate FQ susceptibility of virulent mycobacteria. Abstract : A fast and safe method to analyze the relation between Mycobacterium tuberculosis gyrBA mutations and fluoroquinolone susceptibility was developed using recombinant Mycobacterium smegmatis .